CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hookipa Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hookipa Pharma Inc
350 Fifth Avenue, 72Nd Floor, Suite 7240
NEW YORK, NY  10118  United States Ticker: HOOKHOOK
Business Summary
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics based on its arenavirus platform. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The Company has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board JulieO'Neill 58 8/30/2024 11/1/2018
Chief Executive Officer, Director MaltePeters 61 7/22/2024 1/1/2023
Chief Financial Officer, Executive Vice President, Director TerryCoelho 63 7/22/2024 4/3/2023
6 additional Officers and Directors records available in full report.

Business Names
Business Name
HOOK
Hookipa Biotech GmbH

General Information
Number of Employees: 82 (As of 1/31/2025)
Outstanding Shares: 12,059,039 (As of 2/24/2025)
Shareholders: 1
Stock Exchange: NASD
Federal Tax Id: 815395687
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 19, 2025